Financial Comparison: Dimension Therapeutics (DMTX) and Capricor Therapeutics (CAPR)

Dimension Therapeutics (NASDAQ: DMTX) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Valuation & Earnings

This table compares Dimension Therapeutics and Capricor Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dimension Therapeutics $11.47 million 13.08 -$49.00 million ($2.23) -2.67
Capricor Therapeutics $4.00 million 10.35 -$18.80 million ($0.66) -2.44

Capricor Therapeutics has lower revenue, but higher earnings than Dimension Therapeutics. Dimension Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dimension Therapeutics and Capricor Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dimension Therapeutics -378.28% -240.95% -118.91%
Capricor Therapeutics -464.56% N/A -82.11%

Insider and Institutional Ownership

70.3% of Dimension Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Capricor Therapeutics shares are owned by institutional investors. 2.2% of Dimension Therapeutics shares are owned by company insiders. Comparatively, 28.5% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dimension Therapeutics and Capricor Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dimension Therapeutics 0 4 2 0 2.33
Capricor Therapeutics 0 0 2 0 3.00

Dimension Therapeutics presently has a consensus price target of $5.08, indicating a potential downside of 14.59%. Capricor Therapeutics has a consensus price target of $4.33, indicating a potential upside of 168.63%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Dimension Therapeutics.

Summary

Capricor Therapeutics beats Dimension Therapeutics on 8 of the 12 factors compared between the two stocks.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply